The ε3 and ε4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  To, Alvina W M ^a   Ribe, Elena M ^a   Chuang, Tsu Tshen ^b   Schroeder, Joern E ^c   Lovestone, Simon ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 3; APOLIPOPROTEIN E EPSILON 4; CYCLIN DEPENDENT KINASE 5; EPITOPE; GLYCOGEN SYNTHASE KINASE; GLYCOGEN SYNTHASE KINASE 3ALPHABETA; INSULIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PIOGLITAZONE; PROTEIN KINASE B; SERINE; TAU PROTEIN; THREONINE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLOID PRECURSOR PROTEIN; ANTIDIABETIC AGENT;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENOTYPE; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; LOW FAT DIET; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN PHOSPHORYLATION; TRANSGENE; TREATMENT DURATION; ANIMAL; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; HYPERINSULINISM; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOSPHORYLATION; SOLUBILITY;

ANIMALIA; MUS; MUS MUSCULUS;

ALLELES; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; GENOTYPE; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MICE; PHOSPHORYLATION; SOLUBILITY; TAU PROTEINS; THIAZOLIDINEDIONES;

EID: 79951824233     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016991     Document Type: Article

References (80)

1. Hoyer S, (1991) Abnormalities of glucose metabolism in Alzheimer's disease. Ann N Y Acad Sci 640: 53-58.
2. Lannert H, Hoyer S, (1998) Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 112: 1199-1208.
3. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, et al. (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 9: 13-33.
4. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, et al. (2003) Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 162: 313-319.
5. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, et al. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7: 63-80.
6. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, et al. (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50: 164-168.
7. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
8. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, et al. (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145: 301-308.
9. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, et al. (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53: 1937-1942.
10. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA, (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61: 661-666.
11. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, et al. (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53: 474-481.
12. Cole AR, Astell A, Green C, Sutherland C, (2007) Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev 31: 1046-1063.
13. Gispen WH, Biessels GJ, (2000) Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 23: 542-549.
14. Peila R, Rodriguez BL, Launer LJ, (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51: 1256-1262.
15. Heitner J, Dickson D, (1997) Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 49: 1306-1311.
16. Arvanitakis Z, Wilson RS, Bennett DA, (2006) Diabetes mellitus, dementia, and cognitive function in older persons. J Nutr Health Aging 10: 287-291.
17. Alafuzoff I, Aho L, Helisalmi S, Mannermaa A, Soininen H, (2009) Beta-amyloid deposition in brains of subjects with diabetes. Neuropathol Appl Neurobiol 35: 60-68.
18. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, et al. (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18: 902-904.
19. Freude S, Plum L, Schnitker J, Leeser U, Udelhoven M, et al. (2005) Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 54: 3343-3348.
20. Killick R, Scales G, Leroy K, Causevic M, Hooper C, et al. (2009) Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun 386: 257-262.
21. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, et al. (2003) Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 23: 7084-7092.
22. Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, et al. (2000) Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci 903: 222-228.
23. Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, et al. (2003) Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28: 809-822.
24. Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, et al. (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27: 451-458.
25. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, et al. (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70: 440-448.
26. Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, et al. (2008) Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 131: 3311-3334.
27. Francis G, Martinez J, Liu W, Nguyen T, Ayer A, et al. (2009) Intranasal insulin ameliorates experimental diabetic neuropathy. Diabetes 58: 934-945.
28. Willson TM, Lambert MH, Kliewer SA, (2001) Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 70: 341-367.
29. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, et al. (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13: 950-958.
30. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, et al. (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6: 246-254.
31. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, et al. (2009) Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging.
32. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, et al. (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199: 265-273.
33. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, et al. (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128: 1442-1453.
34. d'Abramo C, Ricciarelli R, Pronzato MA, Davies P, (2006) Troglitazone, a peroxisome proliferator-activated receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells. J Neurochem 98: 1068-1077.
35. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, et al. (2004) Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 24: 10908-10917.
36. d'Abramo C, Massone S, Zingg JM, Pizzuti A, Marambaud P, et al. (2005) Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J 391: 693-698.
37. Bodles AM, Banga A, Rasouli N, Ono F, Kern PA, et al. (2006) Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab 291: E1100-1105.
38. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, et al. (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23: 7504-7509.
39. Clodfelder-Miller BJ, Zmijewska AA, Johnson GV, Jope RS, (2006) Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 55: 3320-3325.
40. Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, et al. (2007) Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci 27: 13635-13648.
41. Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, et al. (2009) Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol.
42. Ke YD, Delerue F, Gladbach A, Gotz J, Ittner LM, (2009) Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 4: e7917.
43. Kim B, Backus C, Oh S, Hayes JM, Feldman EL, (2009) Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 150: 5294-5301.
44. Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, et al. (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res 86: 3265-3274.
45. Plaschke K, Kopitz J, Siegelin M, Schliebs R, Salkovic-Petrisic M, et al. (2010) Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J Alzheimers Dis 19: 691-704.
46. Li ZG, Zhang W, Sima AA, (2007) Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56: 1817-1824.
47. Moroz N, Tong M, Longato L, Xu H, de la Monte SM, (2008) Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimers Dis 15: 29-44.
48. Kohjima M, Sun Y, Chan L, (2010) Increased Food Intake Leads to Obesity and Insulin Resistance in the Tg2576 Alzheimer's Disease Mouse Model. Endocrinology.
49. Julien C, Tremblay C, Phivilay A, Berthiaume L, Emond V, et al. (2008) High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol Aging.
50. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, et al. (2004) Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 101: 3100-3105.
51. Genis I, Gordon I, Sehayek E, Michaelson DM, (1995) Phosphorylation of tau in apolipoprotein E-deficient mice. Neurosci Lett 199: 5-8.
52. Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, et al. (2000) Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol 156: 951-964.
53. Kobayashi M, Ishiguro K, Katoh-Fukui Y, Yokoyama M, Fujita SC, (2003) Phosphorylation state of tau in the hippocampus of apolipoprotein E4 and E3 knock-in mice. Neuroreport 14: 699-702.
54. Harris FM, Brecht WJ, Xu Q, Mahley RW, Huang Y, (2004) Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc. J Biol Chem 279: 44795-44801.
55. Hoe HS, Freeman J, Rebeck GW, (2006) Apolipoprotein E decreases tau kinases and phospho-tau levels in primary neurons. Mol Neurodegener 1: 18.
56. Buttini M, Masliah E, Yu GQ, Palop JJ, Chang S, et al. (2010) Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice. Am J Pathol 177: 563-569.
57. Kummer MP, Heneka MT, (2008) PPARs in Alzheimer's Disease. PPAR Res 2008: 403896.
58. Arbones-Mainar JM, Johnson LA, Altenburg MK, Kim HS, Maeda N, (2010) Impaired adipogenic response to thiazolidinediones in mice expressing human apolipoproteinE4. FASEB J.
59. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE, (2005) Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57: 695-703.
60. Lowell BB, Shulman GI, (2005) Mitochondrial dysfunction and type 2 diabetes. Science 307: 384-387.
61. Gibson GE, Haroutunian V, Zhang H, Park LC, Shi Q, et al. (2000) Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol 48: 297-303.
62. Nakamura T, Watanabe A, Fujino T, Hosono T, Michikawa M, (2009) Apolipoprotein E4 (1-272) fragment is associated with mitochondrial proteins and affects mitochondrial function in neuronal cells. Mol Neurodegener 4: 35.
63. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, et al. (2001) Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A 98: 8838-8843.
64. Chang S, ran Ma T, Miranda RD, Balestra ME, Mahley RW, et al. (2005) Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci U S A 102: 18694-18699.
65. Ljungberg MC, Dayanandan R, Asuni A, Rupniak TH, Anderton BH, et al. (2002) Truncated apoE forms tangle-like structures in a neuronal cell line. Neuroreport 13: 867-870.
66. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, et al. (2003) Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A 100: 10966-10971.
67. Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, et al. (2004) Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 24: 2527-2534.
68. Zhou J, Chen J, Feng Y, (2006) Effect of truncated-ApoE4 overexpression on tau phosphorylation in cultured N2a cells. J Huazhong Univ Sci Technolog Med Sci 26: 272-274.
69. Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB, (2002) Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. J Biol Chem 277: 31781-31788.
70. Wilson-Fritch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, et al. (2004) Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 114: 1281-1289.
71. Bolten CW, Blanner PM, McDonald WG, Staten NR, Mazzarella RA, et al. (2007) Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPAR gamma. Gene Regul Syst Bio 1: 73-82.
72. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, et al. (2009) PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int 55: 496-504.
73. Hardy J, Allsop D, (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12: 383-388.
74. Bales KR, Liu F, Wu S, Lin S, Koger D, et al. (2009) Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci 29: 6771-6779.
75. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, et al. (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106: 1489-1499.
76. Kypreos KE, Karagiannides I, Fotiadou EH, Karavia EA, Brinkmeier MS, et al. (2009) Mechanisms of obesity and related pathologies: role of apolipoprotein E in the development of obesity. FEBS J 276: 5720-5728.
77. Chung SH, (2009) Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. BMB Rep 42: 467-474.
78. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N, (1992) Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A 89: 4471-4475.
79. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, et al. (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 272: 17972-17980.
80. Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, et al. (1999) Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest 103: 1579-1586.